CH5183284

Research use only, not for human use.

CH5183284 is a selective and orally available FGFR inhibitor, which is for FGFR1(IC50=9.3 nM), FGFR2(IC50=7.6 nM), FGFR3(IC50=290), and FGFR4(IC50=22 nM), respectively.

Debio-1347, also known as FF284 and CH5183284, is an orally bioavailable inhibitor of the fibroblast growth factor receptor subtypes 1 (FGFR-1), 2 (FGFR-2) and 3 (FGFR-3), with potential antineoplastic activity. FGFR inhibitor debio 1347 binds to and inhibits FGFR-1, -2, and -3, which result in the inhibition of FGFR-mediated signal transduction pathways. This leads to the inhibition of both tumor cell proliferation and angiogenesis, and causes cell death in FGFR-overexpressing tumor cells.

Debio-1347; Debio 1347; Debio1347; CH5183284

Endocrinology/Hormones

Estrogen Receptor/ERR

FGFR1; FGFR2; FGFR3; FGFR4

Cancer

——

1265229-25-1

356.38

C20H16N6O

95%

DMSO : 25 mg/mL. 70.15 mM;

Cc1nc2c([nH]1)cc(cc2)n1c(c(cn1)C(=O)c1cc2ccccc2[nH]1)N

(5-amino-1-(2-methyl-1H-benzo[d]imidazol-6-yl)-1H-pyrazol-4-yl)(1H-indol-2-yl)methanone

(-20℃)

With Ice Pack

≥ 2 years